Effects of GLP-1 and Combined GLP-1/GIP Treatments in Heart Failure with Mildly Reduced or Normal Heart Pumping

Mushood Ahmed: conceptualization, data curation, project administration, supervision, formal analysis, methodology, software, writing – original draft. Muhammad Burhan: formal analysis, methodology, software, writing – original draft. Aimen Shafiq: writing – original draft. Tallal Mushtaq Hashmi: formal analysis, methodology, software. Raheel Ahmed: writing –reviewing and editing. Marat Fudim: visualization, validation, writing – reviewing, and editing. Robert J. Mentz: visualization, validation, writing – reviewing and editing. Gregg C. Fonarow: conceptualization, data curation, project administration, visualization, validation, writing – reviewing, and editing.

Gregg C. Fonarow reported receiving personal fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Eli Lilly, Johnson & Johnson, Medtronic, Merck, Novartis, and Pfizer outside the submitted work. Marat Fudim reported receiving personal fees from Alleviant, Ajax, Alio Health, Alleviant, Artha, Audicor, Axon Therapies, Bayer, Bodyguide, Bodyport, Boston Scientific, Broadview, Cadence, Cardioflow, Cardionomics, Coridea, CVRx, Daxor, Deerfield Catalyst, Edwards LifeSciences, Echosens, EKO, Feldschuh Foundation, Fire1, FutureCardia, Galvani, Gradient, Hatteras, HemodynamiQ, Impulse Dynamics, Intershunt, Medtronic, Merck, NIMedical, NovoNordisk, NucleusRx, NXT Biomedical, Orchestra, Pharmacosmos, PreHealth, Presidio, Procyreon, ReCor, Rockley, SCPharma, Shifamed, Splendo, Summacor, SyMap, Verily, Vironix, Viscardia, and Zoll; and receiving grants from the National Institutes of Health, Doris Duke, outside the submitted work. Robert J. Mentz has received research support and honoraria from Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Eli Lilly, Medtronic, Medable, Merck, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Relypsa, Respicardia, Roche, Rocket Pharmaceuticals, Sanofi, Verily, Vifor, Windtree Therapeutics, and Zoll. The other authors declare no conflicts of interest.